论文部分内容阅读
甲氧苯酰纤溶酶原链激酶激活剂复合物(APSAC)现通称Anistreplase,是第二代溶栓剂,其优点是可在入院前使用,作者用其治疗首次急性心肌梗塞139例,平均56岁。胸痛开始后平均101(35～180)分于5分钟内静注本品30U,其中由冠心病流动救护车人员给药88例,急诊室或其他病室给药40例,冠心病室给药11例。4～6小时后开始肝素治疗,梗塞后5天开始口服华法令。在给APSAC后3～24小时内将患者随机分成进一步溶栓治疗的介入组和一般治疗组。住院期间作冠脉造影91例,69例在梗塞4天内进
Methylbenzoyl plasminogen streptokinase activator complex (APSAC), now known as Anistreplase, is a second-generation thrombolytic agent with the advantage of being available prior to admission to the hospital with 139 patients treated for the first acute myocardial infarction, with an average of 56 years old. An average of 101 (35-180) minutes after the start of chest pain was intravenously administered for 30 hours within 5 minutes, 88 of whom were ambulatory ambulatory ambulatory officers for coronary heart disease, 40 were given in the emergency department or other wards, and 11 were given coronary heart disease example. 4 to 6 hours after the start of heparin therapy, 5 days after infarction oral warfarin. Within 3 to 24 hours after APSAC, patients were randomized to interventional and general treatment for further thrombolytic therapy. Coronary angiography during hospitalization in 91 cases, 69 cases within 4 days of infarction